Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Soligenix ( (SNGX) ).
On August 18, 2025, Soligenix announced that the FDA granted orphan drug designation to dusquetide, the active ingredient in SGX945, for treating Behçet’s Disease. This designation follows Phase 2a clinical results showing efficacy and safety and provides Soligenix with seven years of U.S. market exclusivity upon FDA approval. The designation also offers financial and regulatory benefits, enhancing Soligenix’s positioning in the rare disease market. Dusquetide has shown promising results in treating Behçet’s Disease, with significant improvements in clinical trials compared to existing treatments, and was well-tolerated without adverse events.
The most recent analyst rating on (SNGX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Soligenix stock, see the SNGX Stock Forecast page.
Spark’s Take on SNGX Stock
According to Spark, TipRanks’ AI Analyst, SNGX is a Underperform.
Soligenix’s overall stock score is primarily driven by its weak financial performance, characterized by declining revenues and persistent losses. While the technical analysis indicates some potential for short-term stability, the valuation and financial metrics suggest ongoing challenges. The company’s recent loan repayment is a positive step towards financial flexibility, but it does not alleviate the underlying financial and operational issues.
To see Spark’s full report on SNGX stock, click here.
More about Soligenix
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs. Their product portfolio includes HyBryte for cutaneous T-cell lymphoma, synthetic hypericin for psoriasis, and dusquetide for inflammatory diseases like oral mucositis and Behçet’s Disease. They also develop vaccines for ricin toxin, filoviruses, and COVID-19 using their ThermoVax heat stabilization technology.
Average Trading Volume: 8,065,638
Technical Sentiment Signal: Sell
Current Market Cap: $11.91M
See more data about SNGX stock on TipRanks’ Stock Analysis page.